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Scs,,lu. Wushin&.ton 
was no’henofil f r patients with inferior infarction h- for 
anterior infarction of >3 h duratioo. 
Since the identification of thrombosis as the precapilating 
event in most cases of transmuml myocardial infarclion. 
thrombolytic therapy has increasingly been applied in their 
treatment (l-3). After initially encouraging results with 
intracoronary therapy, attention has shifted to intravenous 
approaches that might be more broadly applied and allow 
earlier treatmat (4-6). In this report. we present the results 
for myocardial infarct size as defined by quantitative Ihal- 
lium-201 perfusion and global and regional ejection fractions 
by radionuclide ventriculography in survivors of acute myo- 
cardial infarction enrolled in the randomized multicenter 
Western Washington Trial. This trial compared intravenous 
oeplokinase with standard therapy. In this mulw 
~nstitunonal trial. radionuclide studies were performed al a 
vngle ~mstnulion 8 weeks after Ihe acule myocardial infarc- 
tion. 
Methods 
Fwimt relection. Patients were selected for this study in 
27 horpilalr b? 80 physicians in the states of Washington and 
Idaho and !he island of Vancouver, British Columbia be- 
LWCC~ September I. 1983 and July 3 I, 1986. Details ofpalienl 
scleaion. baseline clinical charactenstics. hemodynam+ 
findings and mortalily have been presented elsewhere IT). In 
brief, patients aged ~75 years with signs and symptoms of 
acufc mvacardial infarction including twical chest pain a20 
min in &ration were eligible. Patients who gave informed 
consent for treatment and data collection were randomized 
only when the dumtian of symptoms WBE 56 h. Electrocar- 
diographlc IECG) changes of ST segment elevation m two or 
more leads (at least 0.15 mV in V,. V, or V, or 0.1 mV in a 
standard hmb ieadj and one or m&e iads with ST segment 
eievalmn wkhout Q waves (40 ms duration) were also 
required. 
PorCrrrr ~rcrc rrcladrd ,fiom m,,d~~,,,,;ari~,rr il ~luy had 
my o/ ihc folhmp: I, prcrcnce of other severe dvease 
likely to reduce longevity or ahiluy to cooperate or give 
informed consent (for example. cancer. severe kidney or 
liver dwasc. sepsir. coma or emotional illncssl: 2) prior 
strcptokmax thcmpy: 31 prior coronary artcry bypass sur- 
gcry: 41 any contraindication lo anticoagulant therapy in- 
cluding active peptic ulcer disease. diabetic retinopathy. 
hypertension with diastolic blood pressure >I20 mm Hg. 
recent major wrgical procedure (2 weeks) or neumsurgical 
procedure or lhislory of stroke (4 wecksl, trwma or the 
presence of central catheter lines with uncompressable entry 
sites. 
Patient randomization. Patients who met entry criteria 
were asked In rign an informed consent statement approved 
by the institutional Human Subjects Review Committee at 
each hosoital and were then randomized as follows: II 
amcrior &ocardial infarction ~3 h after Ihe onsel of symp- 
lams: 2) anicrmr myocardial infxciion 3 to 6 h afior symp- 
tom onxt; 31 inferior myocardial infarction ~3 h after 
symptom onset; and 4) inferior myocardial infarction 3 to 6 h 
after symptom onser. 
Tlwr~~ pnricrrrr randmiz~d IO swcp~obbmsr were given 
inlravcnou~ hcnadryl. 50 mg. and hydrocorlisone. 100 mg, 
!o!!wcd hy I .5 milhon unns of streptokinasc inlravenously 
over a 1 h period. Addmonaii; bc,x% ~a\ started at I .&IO 
U/h beginning 2 h afrer the completion of streplokinase and 
contmued with maintenance of the partial thrombaplastin 
time at twice control until anlicoagulalion was stabilized 
with oral warfarin. Control patients received routine coro- 
nary care. which may or may not have included hcparin or 
warfarm ot the discretion of the rcfcrring physician. All other 
medications and therapy were prescribed at the discretion of 
the referring physician, including decisions about coronary 
bypass surgery or angioplasty. 
A !ulul oS 368 poricnrs were cwolled ond rmdomizrd. 
One hundred ninety-one patients were assigned to the treat- 
mcnt group and I77 to the control group. Anterior wall 
mfarc!ion was present in 134 (36%1 and inferior wall infarc- 
tion in 234 (64%). Baseline clinical and hemodynamic char- 
acteristics, including age, gender, ECG iocalion of infarc- 
tion, preseace of prior myocardial infarction, hypotenaion 
delined as systolic blood pressure ~90 mm Hg. shock 
defined as systohc blood pressure ~80 mm Hg wilh periph- 
eral organ dysfunction. ongoing chest pain, pulmonary 
edema and need for cardiovcrsion, were not statistically 
diKerent between the treatment and control groups. Fifty- 
two percent of the patients randomized to active treatment 
were in the group with symptoms of <3 h duration. The 
wage lime from the onset of symptoms to the beginning of 
therapy was 209 min. 
Centralized rsdionuclldc studies. After hospital dis. 
charge, each patient who lived in the Greater Seattle vicin- 
ity, wh!ch WBL defined as a radnts of IM miles from Seattle, 
was asked to return to B central laboratory at the Seattle 
Veterans Administration Hospital for rtudy of ventricular 
function and for quantitrdivc thallium-201 tomography. 
These studies were performed and the results analyzed by 
inwligators who &xc unaware of rhe treatment. assign- 
ment. A total of207 patients underwent thallium tomography 
and 205 patients had ndionuclide ventricular function (com- 
puter malfunction prevented ejection fraction testing in 2 
patients) at an avenge of 8.2 2 7.5 weeks after acute 
myocardial infarction. This represents 62% of the 334 pa- 
tients known to he 8 week survivors of the entife group. One 
hundred ten of the 207 patients had received streptokhtase 
and 97 were control oatients. Aneioolastv or coronaw arterv 
bypass surgery had’been perf&eh in 35 (17%) of;he 20; 
patients having radionuclide testing: 23 (20.9%) of the II0 
treatment patients and I2 (12.4%) of the 97 control patients 
(p = 0. IO for the difference in distribution between treatment 
and control patients). 
Infarct size determined by thalltum-MI tomography. 
lhallium-201. 2 mCi. was injected intravenously after an 
overnight fast with the patient at rest. After I5 min. image 
collection was started with a wide field of view camera (GE 
4W-Tl. which rotated circumferentially about the patient’s 
thorax. Image collection, computer- recons~ruc(ion and 
quantitation of the perfusion defect expressed as a percent of 
the total left ventricular ntass were nerfornted a~ oreviouslv . . 
described by us (8). In brief, M discrete view images were 
collected over the anterior 180” of the bodv in r 128 Y 128 
image format. The iaages were acquired fir 20 s each with 
a low energy, all nurpose collimator. Projection images were 
low pass filtered with a 5 x 5 spatial convolving kernel with 
a frequency cutoff at 0.285 cy&lprojection pixel and then 
hack projected into a 64 x 6-t matrix. Six millimeter planes 
were reconstructed in the transverse plane and then further 
processed to obtain tomograms in the three orthogonal 
perspectives aligned with the cardiac axes as previously 
described bv ES (9.10). In sum. a series of slices encomoass- 
ing the en& he&t along its principal axes was obtained. 
Once reconstructed. the right ventricle was excluded by 
operator intervention and the three-dimensional volume of 
the left ventricle was defined bv edee detection alwrithms 
for each s!ice. This entire three-di~ensianal v&me was 
then quantitated on B slice hv slice basis. Maximal count 
acti& for each short-axis sli& was measured in each of 32 
equally spaced 11.35” vectors projected from the center of 
the slice. The number of counts for each sector was defined 
and count values for each slice were normalized to the 
maximal counts per pixel per sector for the entire heart. For 
each slice, all pixels identified with maximal counts 23 SD 
below the mean from e scrics of healthy young normal 
subjects were identified as abnormal perfusion defects. 
When summed, lhe volume of defect was expressed as a 
percent of the total volume of the left ventricle and subse- 
quently referred to as infarct size. Reproducibility of this 
Ftt 1. Normal ula,,i”!“-20, UImgranl upper tr(l, Four repre- 
sentative short-axis slices fmm base (top lo(t) to apex Rwirr right). 
(xlhogonal cuts are in the superior Ioog axis 01pptr rtgbt, as if 
viewing the short axis from above) and right ante&7 oblique iRA0) 
long axis Rower Mt. similar to the right anterior oblique contxt 
angiogmm). The normal quanthative display is at hwer right: no 
areas fall o&de the normal range and the entire display IS white. 
IReproduced with permission from Cerqucira St. ;:;;ir c. P.itrbe 
IL. Evaluation of mycardial perfusion and iueclion by single 
photon emission compared tomography. Semin Nucl Med 
t987:17:Loo., 
analysis has been previously reporle4 and yielded an R value 
of 0.99 in Ill studies reexamined at a second poict in ttme 
(11.12). 
For display purpusrs, the quantitative three-dimensional 
images were displayed in a single two-dimensional bull’s-eye 
format, as previously developed by us 02). In this display, 
cotmt data for each slice were arranged in a series of 
concemric circles with the basal slices representing the outer 
edges of the circles and the apex the inner portion of the 
circle. For each slice, cou”ts were scaled such that county 
fallins within the normal range are white and thuse falling >3 
SD from the normal we scaled from gray to black depending 
on the magitode of the coont reduction where black = 0 
coonts. These concentric rings with a hull‘s-eye display ore 
oriented in the familiar left anterior oblique or shon-axis 
perspective, preserving the coronary artery distribution. A 
normal study is thus quantitative\y di$ayed as an entirely 
white bull’s-eye (Fig. I). 
we ibnw !)I Figure 2. Infarct location IF %eecn in both Ihr 
standard imues as well as in the ouantitative disolav. The 
mapnitudc oi the defect in the qo’aotitative dirpiay.tcom- 
pared with the total white hull‘a-eye) reflects the perceot of 
the lefi ventnc!e involved. Activity wrx additionally ana- 
lyzed by anatomic regions in which the apex WBF defined ac 
the distal one-third of the left ventricle and the remainder of 
the heart was subdivided into four equal lateral. inferior. 
septal and anterior zones as described 111). 
Ventricular function (ejectton fraction). Once thallium 
imaging had bee” performed, ventricular iun:tion was as- 
sessed on the NIX day at rest with electrocardiographically 
synchronized blwd pool imaging. Red blood cells were 
lahelci w!th 25 mCi of technetwm-59tn and images were 
collec!ed I” the anterior. 45” left anterior oblisue and left 
lateral views. Fourteen consecotive images of i0 rns each 
were co!lected. beainninp. at the It wwe for a total of 3WwO 
cauntslfmme. A s&d&I gamma camera and dedicated nu- 
clear medicine computer were used with a low energy. 
parallel hole, high sensitivity collimator. Global ejection frac- 
lion was calculated from [he left aotetior oblique image and. 
after geometnc localization of the center of activity of this 
same mmge. three regional ejection fractions in the amero- 
septal, inferior and posterolateral zones were also calculaled 
is previously described (It). The accur;ley and precision of 
these methods forourlaboratory hove been dewibed (13.14). 
Staiistical aoalysie. Tomographic infarc: size and mea- 
sures of ventricular function were compared between the 
treatment and control groups by the , test. Because 25 
patients who lived in the cntchment area had died before 
scheduled radionoslide studies. ao alternate statistical anal- . . 
ysis was performed using the SIKOXDU rarer -.. .___ I. . ..“. I%, to 
mcorporate those patients who were not available for study. 
In the rank analysis, patients who had died were given the 
lowest rank for ejection fraction and the highest rank for 
infarct SIX. that is, corresponding to the lowest ejection 
fraction and the largest infarct size. All data are presented as 
the mean ? SD and two p values are routinely listed, the first 
from the I test (excluding deaths) and the second from the 
Wilcoxon rank sum analysis. which includes the deaths. 
Give” the number of comparisons made, these p values mwt 
be regarded as nominal. 
Srepwise logislic regression was also employed to deter- 
mine whether the patients included in this study were 
different from those surviving patients who did “or undergo 
radionuclide testing. Variables included were treatment as- 
signmeot. infarct location. time to randomization, time !o 
hospoalizatlon. prior myocardial infarction. prior congestive 
heart failure, age. wxder. chest pain on admission. herno. 
dynamic stability. hypotenrion. shock. pulmonary edema 
and cardloversion. There were no statistically rignilicant 
differences between the patients who were and were not 
studied. A wand logistic repeession was employed to 
determme whether the patients having radionoclide testing 
inlarct L.LC of 27 * 13% (n = 34) vcrsw 23 t 15% (rr = 31) 
for lreatcd pdlienls (p = 0.26 I lebt: p = 0.08 Wilcoxon test). 
For patients with inferior myocardial infarction. mfarct size 
was 14 + l?%forcootrol(n = 63)vcrw I? 1 il”o(n = 79) 
r0r matment patienti (p = 0.15 t lest: p = 0.13 Wilcoxon 
lest) (k,g. 3). Pslienu were also sahdivided accordin to 
whxher randomization occurred within 3 h of symptom 
onwt. Overall. !mtienls with wm~Mrns of < 3 h duration 
nad im infarct size of 18 2 13% 1-n i 51) for the control group 
versus I3 c 12% (n = 55) in the streptokinase group (P = 
0.05 1 test: p = O.W.5 Wilcoxan ted). For pa&s with 
anterior infarction of ~3 h duration, the infarct size for 
contml patients was 28 + 13% (n = 17) versus 19 2 IS% (n 
Tigm 3. :nk,m iz by quan!i!&e th~!lirm-201 mmyaphy ex- 
pressed as a percent (XT, of the lef, vemricle. Listed p values are 
far r waling. For all patients (left Lx&, there is a 21% limilation in 
infarct size for the slreptokinase Uutched bars, wer control (a*” 
bars) groups. For patients with anterior (ANT) infarction (middle 
bwsL there is a 15% hmaadon (thin is significant by Wdcoxon rank 
sum lest at p = 0.07). The 19% limitation for patients with inferior 
(INF) infarction was not significant (right bars). 
= 15) for treatment patients (p = 0.09 I test: p = 005 
Wilcoxon rest); this is a reduction in infarcf sue I” th>, 
subset of 32% (Fig. 41. For infenor infarcii”n wilh ~3 h 
duration of symptoms. infarct SIX was I3 t IO% (n = 36) for 
c”ntr”l “erS”S I I -r 10% (” = 40, for lrcatmcnt p&m cp = 
Il.31 I test; p = 0.09 Wlk”x”n lest). 
Among all patients with symplom~ of >3 h durarmn. 
infarct siZe in ciotrol patients ~85 20 t 1470 (n = 44) verws 
I6 2 IS% (n = 55) in treatment paients (p = 0.25 r lest. p = 
0.28 Wilaxoon test). Among patients wfh anterior infarctton 
“f ~3 h dsr~!ion of cym?t”zw, infwr! +P wac ?h z 13% 
In = 17) in c”ntrol ~crsus 27 + 14% In = 16) I” lreatmenl 
patients (P = 0.89 1 test: or = 0.69 Wilcoxon lest) (Fig. 4). 
km”“- p&en& with infehor infarction Irealed >3 h after 
““set,;nfarct size am”ngc”ntml patients was I6 f 14% tn = 
27) versus I2 -t 13% (n = 39) in treatment patients (p = 0.28 
I test: p = 0.55 Wilcox”” test). Infarct size in the five 
anatomic subregions was aiso assessed both for all patents 
and for the subsets of patients outbned. There wcrc no 
stadstically significant differences berwren the treatmenl 
and c”ntr”l xr”““s. alrhoueh numeric trend5 “arallelcd the 
global find& _ 
Ventricular fun&on (ejection fractinnl. Overad. left Yen- 
tricular ejection fraction was 47 2 IS% tn = 95) far conlr”I 
patient versus 51 f 15% (n = 110) for treatmenr palicntr 
CD = 0.08 I test: I) = 0.02 Wilcox”” test) (Fix. 5). Thib !> an 
improvement in &ctx”” fraction “f 8% for the streptokinaac 
“ver the control group. Far patients with anterior infaraion. 
ejection fraction was 37 t 15% tn = 33) for the control group 
ven,,s 43 ? 19% (n = 31) fur Ihe atwptokinase group Cp = 
0.14 I test: p = O.G7 Wilcox”” al). For inferior myocardml 
infarction, ejection fracuon was 52 t 12% In = 62) I” Ihc 
patients with anterior infarction of <3 b duwinn of ~ymp- 
tams IFig. 61. For inferior infarction with <3 b durel!an at 
sympfom~. ejection fraction WBS 53 + I I% (n = 35) in 
c”nlr”l verws 52 2 12% (n = 40) I” treated patients (p = 
0.66 I test: p = 0.89 Wdconon lest). For all patientr with ,3 
h dumuan of symptoms. the ejccti”” fraction w+F 45 I 15% 
(n = 44) I” c”mr”l vers”s 50 f IS% (” 7 55) in treated 
patients (p = 0.1 I r test: p = 0.16 Wilcox”” :cct). For 
&or\ wtb ante& infarctlo” and >3 b durar;“” of qymp- 
rams. c,~cL,“n fraction was 36 f 13% In = 171 in conlrol 
wrws 39 + 17% tn = 16) I” treated palienrs Cp = 0.66 I test; 
p - 0.50 Wilc”x”n xstl. For inferior infarctlo” of >3 h 
durauon. qlecu”” fracri”” was 51 t 14% (n = 27) I” caltrol 
and 55 + I?% (n = 39) in lrealment patients (p = 0.21 I test; 
p = 0.55 Wilcoxon test). Regional ejection fi&i”” mcnsllre 
ments were analyzed in the rame subsets of patrent% as 
described and showed no statistically significanr differences 
betwesn ireatmc”~ and c”ntr”l groups. although numeric 
rrendc untformly paralleled rhc global res”lt9. 
Ocher conr~derattons. Scventecn percent of patients who 
had mdionuctide wdirs (35 of 207) had undergone angio- 
plasty orcoronary a~tcry bypass grafting between the time of 
their myacardial infarction and radionuclide studies. The 
results presented were essentially unchanged when these 
patients were excluded from the analyses. Also, two patients 
had had an inrcrcurrenl myocardlal infarction between the 
date of their initial infarction and their radionuclide studies. 
Again, resulu were not modified when these two patients 
v;e’e erc!::+< ~&.e”..~_+-- ‘1 “L, I l/v, , z; or these 337 paiients 
were id ntified as having had a prior myocardial infarction at 
the lime they presented for randomization. When these 19 
patients were excluded from the analysis, the results were 
basically unchanged except in some cases the magnitude of 
difierence between Ihc streptokinase and treatment patients 
was increased. For example. when these patients with prior 
myocardial infarction were excluded and ejection fraction 
was mcarured, ejection fraction overall in control patients 
was 47 ? 15% versus 52 r 14% in treatment patients (p = 
D.OI ! lest; p = 0.009 Wilcoxon test). 
Summary of results. In this trial of intravenously admin- 
islered nrep!okinaae for acute myoardiat infraction, there 
was clear be&l as measured by a reduction in infarct size 
by quantilalive tomographic thallium-201 imaging. There 
was similar benefit for improved ventricular function as 
measured by the global ejection fraction when the statistical 
approach included the patients who had died. When broken 
down by ECG location of infarction and Ihe duration of 
symptoms. essentially all of the benefit accrued to the 
palients with anterior infarction randomized within 3 h ofthe 
onset of symptoms. In this subgroup, infarct size was 
reduced by 32% and ejection fraction improved by 27%. 
There ws no demonstrable bcnelit for patienls with ECG 
inferior myocardial inlbrction or for patients with anterior 
infarction and symptoms of >3 h duration. 
Discussion 
Comparison with other trials. The results of this Study 
document clear be&t :o ~eticn!s with anterior infarction 
given lhrombolytic therapy within 3 h of symptom onset. 
These results thus support the improved survival reported 
for early thrombolytic therapy in both the Gruppo tratiano 
per lo Studio della Strcptochinasi nell’tnfarto (GISSI) (4) and 
the Western Washington intravenous trial (7) and document 
thal Ihe mechanism of benefit is reduction of infarct size and 
consequent improved ventricular function. The results ofthc 
present study arc similar to thn vemrioular function results 
rcponcd by the batravenous Streptokinase in Acute Myocar- 
dial Infarction (ISAM) group (5). This is the only other large 
randomized trial comparing intravenous thrombolytic tber- 
spy with control therapy in which mea~drcment~ of ventri- 
cular function have been reported. In that study, 848 of the 
I.741 patients underwent cardiac catheterization and the 
overall ejection fraction was improved from 54% in control 
patients to 57% in treatment patients. This 3 point improve- 
ment in ejection fraction is similar to the 4 point diffcrcnee 
found in the presenl study. The lSAM group also found 
significant improvement only in patients treated within 3 h of 
the onset of symptoms. although patients were not subdi- 
vided according to anterior and inferior ECG loCations. The 
radionuclidc ejection fraction restilts are also similar to those 
seen in the smaller subset of patients having contrast angi- 
ogwhy ‘110 Ill days atIer infarction in our own study. where 
the control group had an ejection fraction of 51% and the 
rrealmcnt group an ejection fraction of 54% (p = 0.06) (7). 
Our ejection fraction results were also similar to those 
reported from the large randomized trial in the Netherlands 
(15.16L which showed a modest benefit in ejection fraction 
for the rhrombolysis-treated patients. The Netherlands trial 
was largely a trial of intracomnary rather than intravenous 
therapy, although the last I I7 of their 533 patients were 
given intravenous strcptokinase as a prelude to subsequent 
inlracoronary therapy. Treatment in the Netherlands study 
was rcslricted to patients presenting within 4 h of symptom 
onset and the mean time to treatment was 195 min, that is, 
about that of the present intravenous trial. Serial radionu- 
elide ventticulographr was also perfomxd in B subset of 
patients in the Netherlands trial at 48 h, 2 weeks and 3 
months after infarction (16). Significant improvement in 
ejection fraction between the 48 h and the 2 week study WBS 
seen for patients treated with thrombotysia over the control 
patients. At 3 months. only patients with anterior infarction 
in the treatment group showed significant improvement. 
Earlier. smaller trials of inlracoronary thrombolytic therapy 
(17-191 generally lrcaled patients later after symptom onset 
aad failed to show any improvement in left ventricular Although stathtically ugndcant m~pr”veme”t ~a, ev;de”: 
function, with the e~ceptm” of the study reported by .4nder- f~lr patxntr with anterior infarction over&, subxt awlyrir 
son et al. (:9) in which paticot~ were rreared at a” average of Of 1ho,e w,,il Infarctlo” >3 h I” durario” aowed Ihil, 
just under 3 h after symptom onset. e\\e”t,a,,y :,/I of the benef,, W&Y precent ,n lbore treated <3 
Techniques of study. I” this study. patients from mu!@ 
institutions underwent standardwed teqting in a centralircd 
laboratory for both ventricular ftmctio” and mea~ureme”t of 
qunntitative tomographic thallium mfxt riw Tomographic 
infaret size was clearly reduced in lrealed watients and. when 
“o”~!nivors were &idered I” the s~atetical anaiyw. 
measures of ventricular function wcrc alro improved. These 
two radionuclidc tests are quite independent. uith the mea- 
aureme”L of infarct size employing ao npotope t&e” up in rhe 
normal mvocardium and in which three-dimensional. com- 
puter tomographic reconstruction techniques define the ~vol- 
ume of “bnomnl myocardial uptake. Measuring ventricular 
function, on the other hand, ises a wcond mlope and a 
standard (that is. nontomographic) analyrir that IS wdcly 
employed. Tbe fact that these two results are concordant in 
direction and similar in mzgnitude thus substantiates the 
biologic certainty of the results obtained. 
Use of the radionuclide ejection fraction lo quantilate the 
magnitude of myocardial damage. as well as p&g”“% after 
“cute myocardial infarction. is now welt validated in seve:rd 
studies and is considered a standard approach @X Siring of 
the infarct by quantitative thallium-201 tomocraphv is 
newer, but has been validated by others in ex,%r&l 
animals with both technetiutr pyrophosphate and labeled 
fatty acids aq well as thallium-201 (21-23). In patients. 
thallium tamogrwhy has been related to infarct Size as 
rnezwr~J by :a’~~! creatinine !&e:$ x!ivi?j ^-A -sL-. I.>>” YY.l...L 
progllos~s (%25) and war used in a” cartier trial bv us (I I) 
employing intracoronary streptokinase. In additi&the spe- 
cific quantitative approach utilized in the present study was 
developed and validated by us in an experimental animal 
study (12) in wbicb single photon emission computed romo- 
graphic (SPECf) infarct size by thallium-201 correlated 
highly with that defined by lissue counting of involved 
myocardium in vitro. Because the initial distribution of 
thallium-201 closely parallels coronary blood Row. the ex- 
tent to which that can be accurately quantitated externally 
should be a reasonable estimate of infarct size (26). In 
patients with unstable angina syndromes. it is powble that 
the initial distribulio” may represent hypopelfusio” as well 
as infarction and some such patienn having rest thathum-201 
images show redistribution in a !ater study. We have “of 
performed late redistribulion studies in patients in the 
present report because we had previously shown 127) that in 
stable patients. serial studies performed at rest showed no 
redistribution. 
Most benefit to patients with anterior infarction. One 
feature of particular interert in this tnal war the identifica- 
lion of the subset of patients wth anterior infarction <3 h 
duration as the only group :o show definite improvement. 
h from ihe onset of lhrxr symptoms. This dit%r comcwha 
from our wrvival report (7) in whtch padeats aah ant&or 
i”Rwrlo” have a” improved I year XNIVBI a: the p = 0.05 
level and a probably llnproved I4 day survival at the p = O.Oh 
level: however, there were a relatively small number of 
death% I” the overall group with anterior iafarctio” and 
rubw anal+ by >3 or ~3 b for survival did not show 
statistical Ggnificance for either group. The data for palie”:? 
wrh inferior myocardial infarction are entirely concordant 
with wrvival data for inferior infarction in this trial. There 
was no benefit in survival early or lale for patients wirh 
(“f&or infaction There was Gmilarly no difference in 
rad~onuchds indexesbetween ~C~IIECI and control puentr 
w”h tnferior infarction whether they were treated before or 
atier 3 h of the onset of symptoms. %ually all cxperimenlal 
animal data (28.29) and moot clinical slodier report that 
lhrombolytw therapy must be give” within about the first 3 h 
to be effective. For example, Matbey et al. (30) and Simoons 
et al. (31, have suggested that most ofrhe identifiabie benefit 
IS seen among patients tre?.ted within the first Z h of 
Radionuclide studies in this sews were performed 2 
months after the we”! and were thus relatively late. Our 
results prcsuppos~ thai no intervening eventq occurred. This 
was the case because only two of there patientc were known 
10 have rurtained myocardial infarction in the interim and 
.L^ _^ ,...I.. _. 
,,I. _  ,._,u,i, __,I_ .hi SZ,TC ~~hi:b;rc,rr,-’ ;bil ,+ere iiiiliidcd. 
Simdarlv. the results were unchansd whether the 35 (17% 
patients-who had undergone a”gio&rty or coronary artery 
bypass surgery in the intervening 2 months were melt&d or 
“at. Thts relatively late time period for study was a necessily 
in our tnal because paticnto traveled from a vanfty rf 
locat~onr around the state and required some time to stabi- 
lize. Rerullrat this time period should. however. reflect “et 
myocardial damage and infarct rue in that peri-infarctional 
irchcmia should have resolved by thin time and sympathetic 
nervous system overactivity with its associated hypercon. 
tractility in naninfarcted regions should similarly ha% re- 
solved (32.33). 
Comparison with the western WzShlngion Intraco*o”ary 
Trial. One noteworthy fisding in the present study is the 
difference between it and our prior Western Washtwton 
randomized trial of intracoronary rtrep!okinase Cl 1.34). In 
that trial. the same two measures. thal IS. ejection fraction 
and tomographic thallium infarct Gze, were measured in 
survivors I the snme time after infarction. However, no 
d0Tere”ces be: ver” the treatntent and co”tr~l patie.ils were 
we”. I” the present intravenous study. both ejscticn fraction 
and infarct size favored the treatment group. This most 
likely reflects the faei that palienls m the intravenous sludy 
wwc treated on average about an hour earlier than in the 
mtracoronary tnal (209 and 216 min, respectively). In the 
inlrdvcnous trial. 52% of the patents were randomized 
within 3 h of the onber of symptoms, why .eab only 22% of 
patients wcrc randomized within 3 b in the intracomnary 
&. Although studied in a 3 year time period preceding our 
intrxnous trial. the eiection fraction and infarct size for 

